Study: malaria drug-artemisinin conjugate DZ-ART1 targets cancer mitochondria and improves pancreatic cancer outcomes

What happened

Researchers report DZ-ART1, a first-in-class dual-function therapeutic composed of a tumor-targeting heptamethine carbocyanine dye conjugated to artemisinin (ART), originally a malaria drug. In mice, near-infrared imaging showed precise tumor localization, and DZ-ART1 accumulated 5- to 10-fold more in cancer cells than in normal cells. It significantly decreased survival of eight pancreatic ductal adenocarcinoma (PDAC) cell lines with little effect on normal cells and increased the lethal effect of chemotherapies in vitro and in vivo. Functional assays showed DZ-ART1 disrupts mitochondrial bioenergetics, depletes ATP, and induces reactive oxygen species production. Mitochondrial depletion decreased DZ-ART1 uptake and cytotoxicity, indicating a mitochondria-dependent mechanism. In three preclinical models (KPC transgenic, syngeneic, and patient-derived xenografts), DZ-ART1 suppressed tumor growth and metastasis, prolonged survival, and showed no toxicity to normal tissues. The study was published on 16 August 2026 in Scientific Reports.

Why it matters

DZ-ART1 represents a new class of anti-cancer therapeutics that uniquely combines diagnostic imaging with cancer cell organelle-specific targeting. Its mitochondria-dependent action, ability to enhance chemotherapy, and safety profile in preclinical models may offer a promising approach for pancreatic ductal adenocarcinoma, one of the most lethal malignancies.